ReviewmAbs
Mining human antibody repertoires.
Review in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Development and clinical application of recombinant polyclonal antibodies.Frontiers in immunology · 2026Review
- Engineering therapeutic monoclonal antibodies.The Journal of allergy and clinical immunology · 2024Review
- Advancement in the development of single chain antibodies using phage display technology.PeerJ · 2024Article
- Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice.iScience · 2022Article
- Antibody-based cancer therapy.Oncogene · 2021Review
- Protein design and variant prediction using autoregressive generative models.Nature communications · 2021Article
- Infectious disease antibodies for biomedical applications: A mini review of immune antibody phage library repertoire.International journal of biological macromolecules · 2020Review
- Cognizance of Molecular Methods for the Generation of Mutagenic Phage Display Antibody Libraries for Affinity Maturation.International journal of molecular sciences · 2019Review
- Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics.Molecular biotechnology · 2019Review
- Selection of Antibodies with Tailored Properties by Application of High-Throughput Multiparameter Fluorescence-Activated Cell Sorting of Yeast-Displayed Immune Libraries.Molecular biotechnology · 2018Article
- Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies.Cancer immunology research · 2018Article
- A synthetic biology approach for consistent production of plant-made recombinant polyclonal antibodies against snake venom toxins.Plant biotechnology journal · 2018Article
- From rabbit antibody repertoires to rabbit monoclonal antibodies.Experimental & molecular medicine · 2017Review
- A Gradient of Sitewise Diversity Promotes Evolutionary Fitness for Binder Discovery in a Three-Helix Bundle Protein Scaffold.Biochemistry · 2017Article
- Naïve Human Antibody Libraries for Infectious Diseases.Advances in experimental medicine and biology · 2017Review
- Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries.Advances in experimental medicine and biology · 2017Review
- High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals.PloS one · 2017Article
- Article
- Article
- HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species.BMC biotechnology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Human monoclonal antibodies (mAbs) have become drugs of choice for the management of an increasing number of human diseases. Human antibody repertoires provide a rich source for human mAbs. Here we review the characteristics of natural and non-natural human antibody repertoires and their mining with non-combinatorial and combinatorial strategies. In particular, we discuss the selection of human mAbs from naïve, immune, transgenic, and synthetic human antibody repertoires using methods based on hybridoma technology, clonal expansion of peripheral B cells, single-cell PCR, phage display, yeast display, and mammalian cell display. Our reliance on different strategies is shifting as we gain experience and refine methods to the efficient generation of human mAbs with superior pharmacokinetic and pharmacodynamic properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.